hrp0089p2-p256 | Growth & Syndromes P2 | ESPE2018
Ascaso Matamala Angela
, Trujillano Lidon Laura
, Calero Polanco Angelica
, Matute-Llorente Angel
, Bueno Lozano Gloria
Background: Small for gestational age (SGA) children are at increased risk of metabolic syndrome in adulthood and have below-average bone mineral density (BMD). Growth hormone treatment reduces fat mass and insulin sensitivity, increases lean body mass and improves height and BMD in short SGA children. We aimed to evaluate changes in body composition in SGA patients treated with growth hormone (GH), after its cessation, compared with young adults born appropriate for gestation...